Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Global Chronic Myeloid Leukemia (CML) Market Report 2017: Focus on Forecasts, Treatment, Epidemiology, Marketed Drugs & Pipeline | ||
By: PR Newswire Association LLC. - 16 Feb 2018 | Back to overview list |
|
DUBLIN, Feb. 16, 2018 /PRNewswire/ -- The "Chronic Myeloid Leukemia (CML)" report has been added to ResearchAndMarkets.com's offering. Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a myeloproliferative disorder characterized by a single cytogenetic hallmark: the chromosomal translocation t(9;22)(q34;q11), known as the Philadelphia (Ph) chromosome. In a small minority of patients who exhibit the characteristics of CML, the Ph chromosome cannot be detected - this is referred to as Ph-negative CML, or atypical CML. Market Snapshot
Key Topics Covered:
Treatment: Chronic Myeloid Leukemia
Epidemiology: Chronic Myeloid Leukemia In The Us, Japan, And 5EU
Marketed Drugs: Chronic Myeloid Leukemia
Pipeline: Chronic Myeloid Leukemia
For more information about this report visit https://www.researchandmarkets.com/research/k7kr9g/global_chronic?w=5 Media Contact: Laura Wood, Senior Manager View original content:http://www.prnewswire.com/news-releases/global-chronic-myeloid-leukemia-cml-market-report-2017-focus-on-forecasts-treatment-epidemiology-marketed-drugs--pipeline-300600012.html SOURCE Research and Markets |
||
|
||
Copyright 2018 PR Newswire Association LLC. | Back to overview list |